Screening and testing for monoclonal gammopathies: Lessons from the iStopMM screening study​

Since its introduction in 2002, serum free light chains (sFLC) testing has become a key laboratory parameter for diagnosis and management of monoclonal gammopathies. Currently, several immunoassays for determination of sFLC assays are commercially available, of which some designs employ polyclonal antibodies and others monoclonal antibodies, resulting in different value reporting.

This webinar covers the clinical and laboratory aspects that affect serum free light chains testing in diagnosis and monitoring of monoclonal gammopathies, especially with regard to patients with renal impairment and possible misclassification of patients.